However, the widespread implementation of SGLT2 inhibitors in patients with HFrEF and also in patients with HFpEF regardless of T2DM suggest that new biomarkers such irisin are considered useful in the context of improving the discriminative power of current models, even if NT-proBNP levels remain respectively lower. This evidence concerns the gene FNDC5 and type 2 diabetes mellitus.